FBIO (Fortress Biotech) Cyclically Adjusted PS Ratio: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FBIO Fortress Biotech Inc FBIO
45 GF Score
Price $2.92
GF Value $1.28
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Fortress Biotech Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Fortress Biotech  (NAS:FBIO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Fortress Biotech Cyclically Adjusted PS Ratio Related Terms


Fortress Biotech Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech Cyclically Adjusted PS Ratio Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.95 0.94 0.28 0.20 0.35

Fortress Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.35 0.35 0.26 0.00

FBIO vs PMN, VANI, SEER: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Fortress Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Cyclically Adjusted PS Ratio falls into.


FBIO
45GF Score
Fortress Biotech Inc FBIO
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortress Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Fortress Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Fortress Biotech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.589/333.9520*333.9520
=0.589

Current CPI (Jun. 2026) = 333.9520.

Fortress Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.364 241.428 0.503
201612 4.707 241.432 6.511
201703 16.604 243.801 22.744
201706 18.756 244.955 25.570
201709 17.269 246.819 23.365
201712 -41.673 246.524 -56.452
201803 2.082 249.554 2.786
201806 2.357 251.989 3.124
201809 1.731 252.439 2.290
201812 3.128 251.233 4.158
201903 1.523 254.202 2.001
201906 2.582 256.143 3.366
201909 2.578 256.759 3.353
201912 2.798 256.974 3.636
202003 3.052 258.115 3.949
202006 2.069 257.797 2.680
202009 1.868 260.280 2.397
202012 2.584 260.474 3.313
202103 2.150 264.877 2.711
202106 3.305 271.696 4.062
202109 3.888 274.310 4.733
202112 3.278 278.802 3.926
202203 4.161 287.504 4.833
202206 3.192 296.311 3.597
202209 2.772 296.808 3.119
202212 2.715 296.797 3.055
202303 1.830 301.836 2.025
202306 2.357 305.109 2.580
202309 4.634 307.789 5.028
202312 1.855 306.746 2.020
202403 0.760 312.332 0.813
202406 0.813 314.175 0.864
202409 0.743 315.301 0.787
202412 0.581 315.605 0.615
202503 0.497 319.799 0.519
202506 0.550 322.561 0.569
202509 0.533 324.800 0.548
202512 0.529 324.054 0.545
202603 0.418 330.213 0.423
202606 0.589 333.952 0.589

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Fortress Biotech (FBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of $2.92 is trading 127.7% above its estimated GF Value™ of $1.28. GuruFocus considers Fortress Biotech to be Significantly Overvalued.

Key valuation signals for FBIO:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $1.28 vs. price of $2.92 (127.7% above fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
45GF Score

Get the complete analysis for FBIO

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.92
Price
$1.28
GF Value